logo
logo

Avilar Therapeutics Launches With $60 Million Seed Financing To Pioneer Extracellular Protein Degradation

Nov 18, 2021•almost 4 years ago

Amount Raised

$60 Million

Round Type

seed

Waltham

Description

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a $60 million seed financing from founding investor RA Capital Management. Avilar is creating a novel class of protein degrader therapeutics designed to target disease-causing extracellular proteins, extending the reach of protein degradation beyond initial degraders that target intracellular proteins.

Company Information

Company

Avilar Therapeutics

Location

Waltham, Massachusetts, United States

About

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit www.avilar-tx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech